Pay in 4 interest-free payments of $7.28 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
GLP-/GIP dual agonist innovatively integrates the effects of two incretin into one molecule, which can simultaneously activate GLP-1R and GIPR
It can be used as monotherapy or in combination with other diabetes medications, such as metformin or insulin
The next key trend driving the global liraglutide and semaglutide sector expansion lies in the growing evidence that GLP1 agonists improve cardiovascular outcomes, a factor that reshapes prescribing habits and payer policies
Perreault et al., 2022
What also adds to its legitimacy is transparency
US$ 29.67
US$ 28.37
US$ 27.24
US$ 24.33
US$ 22.78
US$ 29.88
US$ 28.78
US$ 21.41
US$ 22.95
